UPDATE 1-Immunodiagnostic profit rises; sees H2 revenue up

* Sees higher revenue in historically stronger H2

* To add 4 new products to IDS-iSYS kit by H1, ’11

* Shares up 4.6 pct to touch all-time high
(Adds details)

Nov 30 (BestGrowthStock) – Britain’s Immunodiagnostic Systems
(IDH.L: ) posted a 44 percent rise in first-half pretax profit,
helped by strong growth in the United States, and forecast
higher revenue in the second half of the year.

Shares of the company, whose kits analyse human blood,
serum, plasma or urine to detect various diseases and measure
vitamin D levels, rose 4.6 percent to touch an all-time high of
1025 pence earlier in the session.

Immunodiagnostic, which is awaiting U.S. regulatory
approval for its automated immunoanalyser IDS-iSYS device,
expects to add four new products to the line by the first half
of 2011.

For the April-September period, Immunodiagnostic reported a
pretax profit of 6.6 million pounds ($10.3 million), compared
with 4.6 million pounds.

Revenue rose 34 percent to 22.6 million pounds, with U.S.
sales up more than 60 percent.

Immunodiagnostic shares, which have gained more than a
third since the company said it was trading in line with its
own view on Aug. 25, were trading at 1020 pence at 0814 GMT on
Tuesday on the London Stock Exchange.
($1=.6423 Pound)
(Reporting by Aditi Samajpati in Bangalore)

UPDATE 1-Immunodiagnostic profit rises; sees H2 revenue up